KALA BIO, Inc. (NASDAQ:KALA) Insider Darius Kharabi Sells 2,021 Shares

KALA BIO, Inc. (NASDAQ:KALA) insider Darius Kharabi sold 2,021 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $7.63, for a total transaction of $15,420.23. Following the completion of the sale, the insider now directly owns 67,807 shares in the company, valued at approximately $517,367.41. This represents a 2.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

KALA BIO Price Performance

Shares of KALA opened at $6.82 on Friday. The firm has a market cap of $31.44 million, a PE ratio of -0.55 and a beta of -2.11. KALA BIO, Inc. has a 52-week low of $4.21 and a 52-week high of $9.25. The business’s 50 day moving average price is $6.70 and its two-hundred day moving average price is $6.33. The company has a debt-to-equity ratio of 3.18, a quick ratio of 2.15 and a current ratio of 2.15.

KALA BIO (NASDAQ:KALA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.93) earnings per share for the quarter, beating the consensus estimate of ($2.43) by $0.50. On average, equities analysts anticipate that KALA BIO, Inc. will post -10.84 EPS for the current year.

Hedge Funds Weigh In On KALA BIO

An institutional investor recently bought a new position in KALA BIO stock. SR One Capital Management LP bought a new stake in KALA BIO, Inc. (NASDAQ:KALA) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO makes up approximately 1.0% of SR One Capital Management LP’s holdings, making the stock its 9th largest holding. SR One Capital Management LP owned approximately 15.76% of KALA BIO at the end of the most recent quarter. Institutional investors and hedge funds own 24.61% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of KALA BIO in a report on Friday, November 15th.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.